Abivax stock skyrocketed in July after the company announced overwhelmingly positive topline results from its Phase 3 ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a ...

Eli Lilly LLY secured a significant milestone on Friday when it became the first company in the healthcare space to reach $1 trillion in market value. With this breakthrough, Lilly is now the second ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

Eli Lilly & Co. is the first pharmaceutical stock to hit a $1 trillion valuation, with its stock’s rise driven by a methodical approach to capturing an obesity-drug market that didn’t exist five years ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...

The booming market for weight-loss drugs has propelled Eli Lilly LLY-0.41%decrease; red down pointing triangle to become the first pharmaceutical company to hit $1 trillion in market capitalization, ...